PDF(Pubmed)
Abstract：
UNASSIGNED: The risk for major adverse cardiovascular events (MACE) with targeted therapies for patients with advanced renal cell carcinoma (RCC) in real-world practice remains unclear.
UNASSIGNED: The aim of this study was to compare the risk for MACE associated with targeted cancer therapies with that associated with cytokine treatment in patients with advanced RCC.
UNASSIGNED: Using Taiwan\'s National Health Insurance Research Database, a retrospective nationwide cohort study was conducted involving patients with advanced RCC who had received targeted therapy (sunitinib, sorafenib, pazopanib, everolimus, or temsirolimus) or cytokine therapy (interleukin-2 or interferon gamma) from 2007 to 2018. Cox proportional hazards models were used to estimate the risk for MACE (a composite of myocardial infarction, ischemic stroke, heart failure, and cardiovascular death) in the cohort using the propensity score method of stabilized inverse probability of treatment weighting.
UNASSIGNED: In this cohort of 2,785 patients with advanced RCC, 2,257 (81%) and 528 (19%) had received targeted and cytokine therapy, respectively. After stabilized inverse probability of treatment weighting, the incidence rates of MACE were 6.65 and 3.36 per 100 person-years in the targeted and cytokine therapy groups, respectively (HR: 1.80; 95% CI: 1.19-2.74). Baseline history of heart failure (HR: 3.88; 95% CI: 2.25-6.71), atrial fibrillation (HR: 3.60; 95% CI: 2.16-5.99), venous thromboembolism (HR: 2.50; 95% CI: 1.27-4.92), ischemic stroke (HR: 1.88; 95% CI: 1.14-3.11), and age ≥ 65 years (HR: 1.81; 95% CI: 1.27-2.58) were independent risk factors for targeted therapy-associated MACE.
UNASSIGNED: Among patients with advanced RCC, the risk for MACE associated with targeted cancer therapy is higher than that associated with cytokine therapy.
UNASSIGNED: The aim of this study was to compare the risk for MACE associated with targeted cancer therapies with that associated with cytokine treatment in patients with advanced RCC.
UNASSIGNED: Using Taiwan\'s National Health Insurance Research Database, a retrospective nationwide cohort study was conducted involving patients with advanced RCC who had received targeted therapy (sunitinib, sorafenib, pazopanib, everolimus, or temsirolimus) or cytokine therapy (interleukin-2 or interferon gamma) from 2007 to 2018. Cox proportional hazards models were used to estimate the risk for MACE (a composite of myocardial infarction, ischemic stroke, heart failure, and cardiovascular death) in the cohort using the propensity score method of stabilized inverse probability of treatment weighting.
UNASSIGNED: In this cohort of 2,785 patients with advanced RCC, 2,257 (81%) and 528 (19%) had received targeted and cytokine therapy, respectively. After stabilized inverse probability of treatment weighting, the incidence rates of MACE were 6.65 and 3.36 per 100 person-years in the targeted and cytokine therapy groups, respectively (HR: 1.80; 95% CI: 1.19-2.74). Baseline history of heart failure (HR: 3.88; 95% CI: 2.25-6.71), atrial fibrillation (HR: 3.60; 95% CI: 2.16-5.99), venous thromboembolism (HR: 2.50; 95% CI: 1.27-4.92), ischemic stroke (HR: 1.88; 95% CI: 1.14-3.11), and age ≥ 65 years (HR: 1.81; 95% CI: 1.27-2.58) were independent risk factors for targeted therapy-associated MACE.
UNASSIGNED: Among patients with advanced RCC, the risk for MACE associated with targeted cancer therapy is higher than that associated with cytokine therapy.
摘要：
■在现实世界实践中，针对晚期肾细胞癌（RCC）患者采用靶向治疗的主要不良心血管事件（MACE）的风险尚不清楚。
■本研究的目的是比较晚期RCC患者与靶向癌症治疗相关的MACE风险和与细胞因子治疗相关的MACE风险。
■使用台湾国民健康保险研究数据库，进行了一项回顾性的全国性队列研究，涉及接受靶向治疗的晚期RCC患者（舒尼替尼，索拉非尼,帕唑帕尼,依维莫司,或替西罗莫司）或细胞因子治疗（白介素2或干扰素γ），从2007年到2018年。Cox比例风险模型用于估计MACE的风险（心肌梗死，缺血性卒中,心力衰竭,和心血管死亡）在队列中使用稳定的治疗加权逆概率的倾向评分方法。
■在2,785名晚期肾癌患者中，2,257（81%）和528（19%）接受了靶向和细胞因子治疗，分别。在治疗加权的逆概率稳定后，靶向治疗组和细胞因子治疗组的MACE发生率分别为6.65和3.36/100人年,分别（HR：1.80；95%CI：1.19-2.74）。基线心力衰竭病史(HR:3.88;95%CI:2.25-6.71),心房颤动（HR：3.60；95%CI：2.16-5.99），静脉血栓栓塞（HR：2.50;95％CI：1.27-4.92），缺血性卒中（HR：1.88；95%CI：1.14-3.11），年龄≥65岁(HR:1.81;95%CI:1.27-2.58)是靶向治疗相关MACE的独立危险因素.
■在晚期肾癌患者中，与靶向癌症治疗相关的MACE风险高于与细胞因子治疗相关的MACE风险.
■本研究的目的是比较晚期RCC患者与靶向癌症治疗相关的MACE风险和与细胞因子治疗相关的MACE风险。
■使用台湾国民健康保险研究数据库，进行了一项回顾性的全国性队列研究，涉及接受靶向治疗的晚期RCC患者（舒尼替尼，索拉非尼,帕唑帕尼,依维莫司,或替西罗莫司）或细胞因子治疗（白介素2或干扰素γ），从2007年到2018年。Cox比例风险模型用于估计MACE的风险（心肌梗死，缺血性卒中,心力衰竭,和心血管死亡）在队列中使用稳定的治疗加权逆概率的倾向评分方法。
■在2,785名晚期肾癌患者中，2,257（81%）和528（19%）接受了靶向和细胞因子治疗，分别。在治疗加权的逆概率稳定后，靶向治疗组和细胞因子治疗组的MACE发生率分别为6.65和3.36/100人年,分别（HR：1.80；95%CI：1.19-2.74）。基线心力衰竭病史(HR:3.88;95%CI:2.25-6.71),心房颤动（HR：3.60；95%CI：2.16-5.99），静脉血栓栓塞（HR：2.50;95％CI：1.27-4.92），缺血性卒中（HR：1.88；95%CI：1.14-3.11），年龄≥65岁(HR:1.81;95%CI:1.27-2.58)是靶向治疗相关MACE的独立危险因素.
■在晚期肾癌患者中，与靶向癌症治疗相关的MACE风险高于与细胞因子治疗相关的MACE风险.
